| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6096185 | Gastroenterology | 2013 | 8 Pages |
Abstract
SVR12 and SVR24 measurements were concordant in a large population of subjects with HCV infection who participated in clinical trials with various treatment regimens and durations. SVR12 is suitable as a primary end point for regulatory approval. SVR4 might be used to guide dose and treatment strategies in trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Jianmeng Chen, Jeffry Florian, Wendy Carter, Russell D. Fleischer, Thomas S. Hammerstrom, Pravin R. Jadhav, Wen Zeng, Jeffrey Murray, Debra Birnkrant,